AlgiPharma is a clinical stage biopharmaceutical company with a focus on developing its proprietary alginate technology for:
* Delivery platforms for nanoparticles, small and large molecule based drugs.
* Drug conjugates, adding functionality and reducing toxicity of parent compound.
* Stand alone API in disease areas such as cystic fibrosis, COPD, and infectious diseases.
AlgiPharma has pharmaceutical scale production capabilities for its technology protected by a broad family of patents.
Our aim is to address unmet medical needs and fight diseases effectively through our innovative alginate technologies. Our alginate technology targets those diseases where there is a clinical need to mitigate abnormal mucus accumulation, microbial infection, biofilm formation and antibiotic resistance.